Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Total Debt (2016 - 2025)

Adma Biologics' Total Debt history spans 13 years, with the latest figure at $72.1 million for Q4 2025.

  • For Q4 2025, Total Debt changed 0.27% year-over-year to $72.1 million; the TTM value through Dec 2025 reached $72.1 million, changed 0.27%, while the annual FY2025 figure was $72.1 million, 0.27% changed from the prior year.
  • Total Debt reached $72.1 million in Q4 2025 per ADMA's latest filing, roughly flat from $72.4 million in the prior quarter.
  • In the past five years, Total Debt ranged from a high of $144.3 million in Q1 2023 to a low of $72.1 million in Q4 2025.
  • Average Total Debt over 5 years is $111.1 million, with a median of $116.0 million recorded in 2023.
  • Peak YoY movement for Total Debt: skyrocketed 526.22% in 2021, then tumbled 44.61% in 2024.
  • A 5-year view of Total Debt shows it stood at $94.9 million in 2021, then soared by 50.56% to $142.8 million in 2022, then dropped by 8.57% to $130.6 million in 2023, then crashed by 44.61% to $72.3 million in 2024, then decreased by 0.27% to $72.1 million in 2025.
  • Per Business Quant, the three most recent readings for ADMA's Total Debt are $72.1 million (Q4 2025), $72.4 million (Q3 2025), and $73.4 million (Q2 2025).